Literature DB >> 12884162

Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.

Kevin B Anderson1, James S Tan, Thomas M File, Joseph R DiPersio, Barbara M Willey, Donald E Low.   

Abstract

We describe 4 patients infected with levofloxacin-resistant pneumococci after therapy for community-acquired pneumonia (CAP). The 4 patients had 15 episodes of CAP; Streptococcus pneumoniae was isolated from blood or sputum samples obtained during 14 of the episodes. The underlying medical condition was Bruton agammaglobulinemia in 3 patients and chronic lymphoid leukemia in the other. The initial episode of CAP in each patient was due to a levofloxacin-susceptible strain. One of 4 reinfections and 5 of 6 relapses were due to levofloxacin-resistant strains. All of these strains had amino acid substitutions in the quinolone-resistance-determining region of the genes parC and gyrA. The time between episodes of pneumonia varied from 1 to 4 months. In immunocompromised patients with suspected or proven pneumococcal infection, it may be prudent not to use fluoroquinolone monotherapy empirically when the patient has a history of fluoroquinolone therapy in at least the past 4 months.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884162     DOI: 10.1086/376642

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

Review 1.  Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.

Authors:  C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

3.  Upgrading antibiotic use within a class: tradeoff between resistance and treatment success.

Authors:  Y Claire Wang; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-13       Impact factor: 11.205

4.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 5.  Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management.

Authors:  J D Fuller; A McGeer; D E Low
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

6.  Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy.

Authors:  M W R Pletz; L McGee; O Burkhardt; H Lode; K P Klugman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-01       Impact factor: 3.267

7. 

Authors:  J Solera; G Jarava
Journal:  Medicine (Madr)       Date:  2009-01-06

Review 8.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

10.  Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.

Authors:  Samir N Patel; Roberto Melano; Allison McGeer; Karen Green; Donald E Low
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-18       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.